Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
NCT ID: NCT00338650
Last Updated: 2007-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1000 participants
INTERVENTIONAL
2006-06-30
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
adalimumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failed prior infliximab therapy.
* Patient is judged to be in generally good health as determined by the principal investigator.
Exclusion Criteria
* Patient considered by the investigator, for any reason, to be an unsuitable candidate
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beverly Paperiello
Role: STUDY_DIRECTOR
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Jonesboro, Arkansas, United States
Little Rock, Arkansas, United States
Roseville, California, United States
San Francisco, California, United States
Englewood, Colorado, United States
Wheat Ridge, Colorado, United States
Bridgeport, Connecticut, United States
Hamden, Connecticut, United States
Clearwater, Florida, United States
Gainesville, Florida, United States
Gainesville, Florida, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
North Miami Beach, Florida, United States
Winter Park, Florida, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Conyers, Georgia, United States
Marietta, Georgia, United States
Savannah, Georgia, United States
Arlington Heights, Illinois, United States
Moline, Illinois, United States
Rockford, Illinois, United States
Columbus, Indiana, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Clive, Iowa, United States
Davenport, Iowa, United States
Overland Park, Kansas, United States
Topeka, Kansas, United States
Lexington, Kentucky, United States
Annapolis, Maryland, United States
Chevy Chase, Maryland, United States
Lutherville, Maryland, United States
Silver Spring, Maryland, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Burlington, Massachusetts, United States
Troy, Michigan, United States
Plymouth, Minnesota, United States
Picayune, Mississippi, United States
Kansas City, Missouri, United States
Mexico, Missouri, United States
St Louis, Missouri, United States
Lebanon, New Hampshire, United States
Egg Harbor, New Jersey, United States
Glen Ridge, New Jersey, United States
Manalapan, New Jersey, United States
Great Neck, New York, United States
Lake Success, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Rochester, New York, United States
Charlotte, North Carolina, United States
Charlotte, North Carolina, United States
Jacksonville, North Carolina, United States
Rocky Mount, North Carolina, United States
Wilmington, North Carolina, United States
Wilmington, North Carolina, United States
Beachwood, Ohio, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Warren, Ohio, United States
Tulsa, Oklahoma, United States
Tulsa, Oklahoma, United States
Portland, Oregon, United States
Portland, Oregon, United States
Beaver Falls, Pennsylvania, United States
Duncansville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Sayre, Pennsylvania, United States
Columbia, South Carolina, United States
Chattanooga, Tennessee, United States
Chattanooga, Tennessee, United States
Germantown, Tennessee, United States
Austin, Texas, United States
South Ogden, Utah, United States
Norfolk, Virginia, United States
Bellevue, Washington, United States
Seattle, Washington, United States
Spokane, Washington, United States
Vancouver, Washington, United States
Milwaukee, Wisconsin, United States
Milwaukee, Wisconsin, United States
Milwaukee, Wisconsin, United States
Monroe, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHOICE
Identifier Type: -
Identifier Source: secondary_id
M06-808
Identifier Type: -
Identifier Source: org_study_id